IMMUNE THERAPY INFLUENCE ON a-DEFENSIN LEVEL IN PERIPHERAL BLOOD NEUTROPHILES IN PYODERMIA PATIENTS

Background. The purpose was to investigate a-defensin levels in neutrophiles of pyodermia patients in comparison
with healthy donors, to estimate clinical efficiency of glucosaminyl muramyl dipeptide (Licopid) and its influence on a-defensin levels.
Materials and method. 31 patients with pyodermia and 17 healthy donors were investigated. Intracellular a-defensin
levels in neutrophiles in the peripheral blood were estimated by flow cytometry with mouse anti-NPantibodies (Hy
cult biotechnology). All patients with pyodermia were treated with Licopid 10 mg once a day within 10 days. Clinical
and laboratory results were measured after 7-0 days course of treatment and one month after treatment.
Results. The a-defensin level in patients with pyodermia was reduced in comparison with healthy donors. Immune
therapy with licopid 10 mg once a day as a complex treatment lead to a-defensin level increase in leukocytes
of peripheral blood.
Conclusion. The treatment with licopid 10 mg a day lead to prolonged remission and to increase of endocellular
a-defensin level. Definition of a-defensin levels can be useful for advisability and for selection of immune
therapy in pyodermia patients. Thus, a decrease of a-defensin levels in pyodermia patients, possibly, is a marker
of the chronic bacterial inflammation.

immunomodulators, peptidoglican, glucosaminyl muramyl dipeptide, antimicrobial peptides, a-defensins, b-defensins, pyodermia